Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + carvedilol
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of entecavir, a nucleoside analogue used to treat chronic hepatitis B, and carvedilol, a non-selective beta-adrenergic antagonist used to treat heart failure, hypertension, and left ventricular dysfunction. While one source indicates no interaction is expected between these medications, another suggests that entecavir may decrease the metabolism of carvedilol, potentially increasing carvedilol levels.
02
Targets
ADRA1A (α1A)ADRB1 (β1)ADRB2 (β2)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on entecavir + carvedilol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + carvedilol.